Detalhe da pesquisa
1.
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Blood
; 143(3): 258-271, 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37879074
2.
Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma.
Blood
; 139(26): 3708-3721, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35090171
3.
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
Blood
; 137(3): 323-335, 2021 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32967009
4.
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Biol Blood Marrow Transplant
; 26(1): 26-33, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31419568
5.
Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
Biol Blood Marrow Transplant
; 26(1): 34-43, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31605820
6.
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
Am J Hematol
; 96(10): E362-E367, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34137072
7.
Rhizopus arrhizus and Fusarium solani Concomitant Infection in an Immunocompromised Host.
Mycopathologia
; 181(1-2): 125-9, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26346377
8.
Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients.
Br J Haematol
; 190(5): e316-e320, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32567678
9.
Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Blood Adv
; 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607381
10.
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.
Front Pediatr
; 11: 1305657, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38283399
11.
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 23(6): 456-462, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37003846
12.
AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells.
Cancer Immunol Res
; 11(9): 1222-1236, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37378662
13.
An unusual case of aggressive malignant spread of epithelioid hemangioendothelioma.
Rare Tumors
; 13: 20363613211010858, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33959241
14.
Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.
Cancer Immunol Res
; 9(9): 1035-1046, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244299
15.
Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.
Leukemia
; 34(6): 1577-1587, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31974434
16.
Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Cancers (Basel)
; 12(9)2020 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32825022
17.
A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hematopoietic cell transplantation.
Leuk Lymphoma
; 60(11): 2754-2761, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31014151
18.
Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy.
Blood Adv
; 7(8): 1572-1576, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36219588
19.
Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents.
Blood Adv
; 6(17): 5227-5231, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358999
20.
CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes.
Blood Cancer J
; 11(3): 54, 2021 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33707412